Cargando…

The Anti-Atherosclerotic Action of FFAR4 Agonist TUG-891 in ApoE–Knockout Mice Is Associated with Increased Macrophage Polarization towards M2 Phenotype

Background: Over the past few years, a better understanding of the biology of G-protein coupled receptors (GPRs) has led to the identification of several receptors as novel targets for free fatty acids (FFAs). FFAR4 has received special attention in the context of chronic inflammatory diseases, incl...

Descripción completa

Detalles Bibliográficos
Autores principales: Kiepura, Anna, Stachyra, Kamila, Wiśniewska, Anna, Kuś, Katarzyna, Czepiel, Klaudia, Suski, Maciej, Ulatowska-Białas, Magdalena, Surmiak, Marcin, Olszanecki, Rafał
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8471331/
https://www.ncbi.nlm.nih.gov/pubmed/34575934
http://dx.doi.org/10.3390/ijms22189772
_version_ 1784574437226446848
author Kiepura, Anna
Stachyra, Kamila
Wiśniewska, Anna
Kuś, Katarzyna
Czepiel, Klaudia
Suski, Maciej
Ulatowska-Białas, Magdalena
Surmiak, Marcin
Olszanecki, Rafał
author_facet Kiepura, Anna
Stachyra, Kamila
Wiśniewska, Anna
Kuś, Katarzyna
Czepiel, Klaudia
Suski, Maciej
Ulatowska-Białas, Magdalena
Surmiak, Marcin
Olszanecki, Rafał
author_sort Kiepura, Anna
collection PubMed
description Background: Over the past few years, a better understanding of the biology of G-protein coupled receptors (GPRs) has led to the identification of several receptors as novel targets for free fatty acids (FFAs). FFAR4 has received special attention in the context of chronic inflammatory diseases, including atherosclerosis, obesity and NAFLD, through to its anti-inflammatory effect. Methods: The present study investigates the influence of prolonged treatment with TUG-891-FFAR4 agonist on the development of atherosclerosis plaque in apoE-knockout mice, using morphometric and molecular methods. Results: TUG-891 administration has led to the reduction of atherosclerotic plaque size and necrotic cores in an apoE-knockout mice model. TUG-891-treated mice were administered subcutaneously at a dose of 20 mg/kg three times a week for 4 months. The FFAR4 agonist reduced the content of pro-inflammatory M1-like macrophages content in atherosclerotic plaques, as evidenced by immunohistochemical phenotyping and molecular methods. In atherosclerotic plaque, the population of smooth muscle cells increased as evidenced by α-SMA staining. We observed changes in G-CSF and eotaxin markers in the plasma of mice; changes in the levels of these markers in the blood may be related to macrophage differentiation. Importantly, we observed a significant increase in M2-like macrophage cells in atherosclerotic plaque and peritoneum. Conclusions: Prolonged administration of TUG-891 resulted in significant amelioration of atherogenesis, providing evidence that the strategy based on macrophage phenotype switching toward an M2-like activation state via stimulation of FFAR4 receptor holds promise for a new approach in the prevention or treatment of atherosclerosis.
format Online
Article
Text
id pubmed-8471331
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-84713312021-09-27 The Anti-Atherosclerotic Action of FFAR4 Agonist TUG-891 in ApoE–Knockout Mice Is Associated with Increased Macrophage Polarization towards M2 Phenotype Kiepura, Anna Stachyra, Kamila Wiśniewska, Anna Kuś, Katarzyna Czepiel, Klaudia Suski, Maciej Ulatowska-Białas, Magdalena Surmiak, Marcin Olszanecki, Rafał Int J Mol Sci Article Background: Over the past few years, a better understanding of the biology of G-protein coupled receptors (GPRs) has led to the identification of several receptors as novel targets for free fatty acids (FFAs). FFAR4 has received special attention in the context of chronic inflammatory diseases, including atherosclerosis, obesity and NAFLD, through to its anti-inflammatory effect. Methods: The present study investigates the influence of prolonged treatment with TUG-891-FFAR4 agonist on the development of atherosclerosis plaque in apoE-knockout mice, using morphometric and molecular methods. Results: TUG-891 administration has led to the reduction of atherosclerotic plaque size and necrotic cores in an apoE-knockout mice model. TUG-891-treated mice were administered subcutaneously at a dose of 20 mg/kg three times a week for 4 months. The FFAR4 agonist reduced the content of pro-inflammatory M1-like macrophages content in atherosclerotic plaques, as evidenced by immunohistochemical phenotyping and molecular methods. In atherosclerotic plaque, the population of smooth muscle cells increased as evidenced by α-SMA staining. We observed changes in G-CSF and eotaxin markers in the plasma of mice; changes in the levels of these markers in the blood may be related to macrophage differentiation. Importantly, we observed a significant increase in M2-like macrophage cells in atherosclerotic plaque and peritoneum. Conclusions: Prolonged administration of TUG-891 resulted in significant amelioration of atherogenesis, providing evidence that the strategy based on macrophage phenotype switching toward an M2-like activation state via stimulation of FFAR4 receptor holds promise for a new approach in the prevention or treatment of atherosclerosis. MDPI 2021-09-09 /pmc/articles/PMC8471331/ /pubmed/34575934 http://dx.doi.org/10.3390/ijms22189772 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Kiepura, Anna
Stachyra, Kamila
Wiśniewska, Anna
Kuś, Katarzyna
Czepiel, Klaudia
Suski, Maciej
Ulatowska-Białas, Magdalena
Surmiak, Marcin
Olszanecki, Rafał
The Anti-Atherosclerotic Action of FFAR4 Agonist TUG-891 in ApoE–Knockout Mice Is Associated with Increased Macrophage Polarization towards M2 Phenotype
title The Anti-Atherosclerotic Action of FFAR4 Agonist TUG-891 in ApoE–Knockout Mice Is Associated with Increased Macrophage Polarization towards M2 Phenotype
title_full The Anti-Atherosclerotic Action of FFAR4 Agonist TUG-891 in ApoE–Knockout Mice Is Associated with Increased Macrophage Polarization towards M2 Phenotype
title_fullStr The Anti-Atherosclerotic Action of FFAR4 Agonist TUG-891 in ApoE–Knockout Mice Is Associated with Increased Macrophage Polarization towards M2 Phenotype
title_full_unstemmed The Anti-Atherosclerotic Action of FFAR4 Agonist TUG-891 in ApoE–Knockout Mice Is Associated with Increased Macrophage Polarization towards M2 Phenotype
title_short The Anti-Atherosclerotic Action of FFAR4 Agonist TUG-891 in ApoE–Knockout Mice Is Associated with Increased Macrophage Polarization towards M2 Phenotype
title_sort anti-atherosclerotic action of ffar4 agonist tug-891 in apoe–knockout mice is associated with increased macrophage polarization towards m2 phenotype
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8471331/
https://www.ncbi.nlm.nih.gov/pubmed/34575934
http://dx.doi.org/10.3390/ijms22189772
work_keys_str_mv AT kiepuraanna theantiatheroscleroticactionofffar4agonisttug891inapoeknockoutmiceisassociatedwithincreasedmacrophagepolarizationtowardsm2phenotype
AT stachyrakamila theantiatheroscleroticactionofffar4agonisttug891inapoeknockoutmiceisassociatedwithincreasedmacrophagepolarizationtowardsm2phenotype
AT wisniewskaanna theantiatheroscleroticactionofffar4agonisttug891inapoeknockoutmiceisassociatedwithincreasedmacrophagepolarizationtowardsm2phenotype
AT kuskatarzyna theantiatheroscleroticactionofffar4agonisttug891inapoeknockoutmiceisassociatedwithincreasedmacrophagepolarizationtowardsm2phenotype
AT czepielklaudia theantiatheroscleroticactionofffar4agonisttug891inapoeknockoutmiceisassociatedwithincreasedmacrophagepolarizationtowardsm2phenotype
AT suskimaciej theantiatheroscleroticactionofffar4agonisttug891inapoeknockoutmiceisassociatedwithincreasedmacrophagepolarizationtowardsm2phenotype
AT ulatowskabiałasmagdalena theantiatheroscleroticactionofffar4agonisttug891inapoeknockoutmiceisassociatedwithincreasedmacrophagepolarizationtowardsm2phenotype
AT surmiakmarcin theantiatheroscleroticactionofffar4agonisttug891inapoeknockoutmiceisassociatedwithincreasedmacrophagepolarizationtowardsm2phenotype
AT olszaneckirafał theantiatheroscleroticactionofffar4agonisttug891inapoeknockoutmiceisassociatedwithincreasedmacrophagepolarizationtowardsm2phenotype
AT kiepuraanna antiatheroscleroticactionofffar4agonisttug891inapoeknockoutmiceisassociatedwithincreasedmacrophagepolarizationtowardsm2phenotype
AT stachyrakamila antiatheroscleroticactionofffar4agonisttug891inapoeknockoutmiceisassociatedwithincreasedmacrophagepolarizationtowardsm2phenotype
AT wisniewskaanna antiatheroscleroticactionofffar4agonisttug891inapoeknockoutmiceisassociatedwithincreasedmacrophagepolarizationtowardsm2phenotype
AT kuskatarzyna antiatheroscleroticactionofffar4agonisttug891inapoeknockoutmiceisassociatedwithincreasedmacrophagepolarizationtowardsm2phenotype
AT czepielklaudia antiatheroscleroticactionofffar4agonisttug891inapoeknockoutmiceisassociatedwithincreasedmacrophagepolarizationtowardsm2phenotype
AT suskimaciej antiatheroscleroticactionofffar4agonisttug891inapoeknockoutmiceisassociatedwithincreasedmacrophagepolarizationtowardsm2phenotype
AT ulatowskabiałasmagdalena antiatheroscleroticactionofffar4agonisttug891inapoeknockoutmiceisassociatedwithincreasedmacrophagepolarizationtowardsm2phenotype
AT surmiakmarcin antiatheroscleroticactionofffar4agonisttug891inapoeknockoutmiceisassociatedwithincreasedmacrophagepolarizationtowardsm2phenotype
AT olszaneckirafał antiatheroscleroticactionofffar4agonisttug891inapoeknockoutmiceisassociatedwithincreasedmacrophagepolarizationtowardsm2phenotype